Public Profile

Curia

Curia Global, commonly referred to as Curia, is a leading contract research, development, and manufacturing organisation headquartered in the United States. Established in 2019, Curia has rapidly expanded its operational footprint across North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Specialising in drug development and manufacturing, Curia offers a comprehensive suite of services, including analytical testing, formulation development, and commercial manufacturing. What sets Curia apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a strong market presence, Curia has achieved significant milestones, including strategic acquisitions that enhance its capabilities. The company is recognised for its expertise in complex drug modalities, making it a trusted partner for clients seeking to navigate the complexities of drug development.

DitchCarbon Score

How does Curia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

32

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Curia's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Let us know if this data was useful to you

Curia's reported carbon emissions

In 2022, Curia Global, Inc. reported total carbon emissions of approximately 41,290,410 kg CO2e for Scope 1 and about 46,508,720 kg CO2e for Scope 2. This consistent data from 2021 and 2022 indicates a stable emissions profile, with no reported Scope 3 emissions. Curia has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which Curia joined in 2024, demonstrating its dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. The company is actively working towards its climate goals, although specific near-term reduction targets have not been disclosed. Curia's ongoing efforts reflect a proactive approach to sustainability and environmental responsibility in its operations based in the United States.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20212022
Scope 1
41,290,410
00,000,000
Scope 2
46,508,720
00,000,000
Scope 3
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Curia's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Curia is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Curia is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Par Pharmaceutical

US
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Twist Bioscience Corporation

US
Health and social work services (85)
Updated 20 days ago

PRA Health Sciences, Inc.

US
Research and development services (73)
Updated about 8 hours ago

Cambrex Karlskoga

SE
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Lonza

CH
Furniture; other manufactured goods n.e.c. (36)
Updated about 8 hours ago

Emergent BioSolutions

US
Research and development services (73)
Updated 22 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers